Carpenter (CRS) could produce exceptional returns because of its solid growth attributes.

Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is how Carpenter Technology (CRS) and Rio Tinto (RIO) have performed compared to their sector so far this year.

Caxton Associates LLP reduced its stake in Carpenter Technology Corporation (NYSE: CRS) by 52.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,153 shares of the basic materials company's stock after selling 5,598 shares during the period.

Carpenter Technology Corporation (NYSE: CRS - Get Free Report) COO Brian Malloy sold 4,130 shares of Carpenter Technology stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $303.52, for a total transaction of $1,253,537.60. Following the completion of the transaction, the chief operating officer directly owned 78,875 shares

FORA Capital LLC increased its stake in Carpenter Technology Corporation (NYSE: CRS) by 90.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 10,791 shares of the basic materials company's stock after purchasing an additional 5,123 shares during the quarter. FORA Capital LLC's

Carpenter Technology Corporation (NYSE: CRS - Get Free Report) COO Brian Malloy sold 27,640 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $305.60, for a total value of $8,446,784.00. Following the sale, the chief operating officer directly owned 78,875 shares of the company's stock,

Rising demand for new-generation jet engines is driving much of the growth.

California Public Employees Retirement System raised its holdings in Carpenter Technology Corporation (NYSE: CRS) by 6.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 94,089 shares of the basic materials company's stock after buying an additional 5,335 shares during the period. California

Cavendish has taken an upbeat view of Poolbeg Pharma PLC's (AIM:POLB, OTC:POLBF) prospects after the company's anti-inflammatory candidate POLB 001 was selected as a central element of a major UK research programme into cytokine release syndrome. CRS is a dangerous immune reaction that can occur during advanced cancer treatments such as bispecific antibodies and CAR-T therapies.